Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Kuros announces CEO succession
– Commercialization veteran and life science executive Dr. Ivan Cohen-Tanugi named Chief Executive Officer of Kuros
– Didier Cowling will serve as President on the Executive Committee and remain on the Board of Directors
Kuros Biosciences Ltd announced today that Dr. Ivan Cohen-Tanugi has been appointed Chief Executive Officer with effect as of April 13, 2017. Dr. Cohen-Tanugi will be proposed for election to the Board of Directors at the next General Meeting. He succeeds Didier Cowling, who continues to serve the Company as President and remains a member of the Executive Committee and the Board.
Schlieren (Zurich), Switzerland, April 13, 2017
Dr. Cohen-Tanugi joins Kuros with more than 20 years of experience in leadership roles in the life sciences industry. He held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys. He received his medical degree at Grenoble School of Medicine, France, and obtained a MBA at H.E.C. Business School, Paris, France. Dr. Cohen-Tanugi is French and US citizen.
Didier Cowling, said: “It has been a privilege to build Kuros from inception to reaching commercial stage and I am extremely proud of what our team has accomplished. The next phase in the Company’s development requires an experienced commercial leader and I am very pleased that we have attracted Ivan as the next CEO. I am looking forward to supporting Ivan and the team to help realize our vision of building a leading orthobiologics company.”
Dr. Ivan Cohen-Tanugi commented: ”I am excited to join Kuros at its transition to becoming a commercial orthobiologics company. MagnetOs and Neuroseal are innovative products that address important medical needs and will form a strong foundation for the future development of the business. Our pipeline of biological bone graft substitutes KUR-111, KUR-112 and KUR-113 has the potential to further drive Kuros’ growth. I am looking forward to working with the Kuros team, Didier and the Board to shape a standout company.”
Dr. Christian Itin, Chairman of the Board said: “We are delighted to welcome Ivan as CEO of Kuros Biosciences. His extensive experience in building and leading commercial teams will be key to a successful launch of MagnetOs and Neuroseal. The transition marks the successful completion of the startup phase of Kuros and its maturation into a commercial orthobiologics company. On behalf of the Board and the Company, I thank Didier for successfully building Kuros through the startup and development stage and for leading the Company through a period of significant change. His extensive knowledge of the orthobiologics space will be an invaluable resource and support the further development of the Company.”
About Kuros Biosciences Ltd
Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kuros.ch for additional information on Kuros, its science and product pipeline.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46